SKB BIO-B (06990) announced that three of its products have been included in the National Reimbursement Drug List (NRDL) released by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security on December 7, 2025. The products are ADC Sacituzumab Tirumotecan (sac-TMT, also known as SKB264/MK-2870, brand name: Jiatailai®), Cetuximab N01 Injection (formerly A140, brand name: Datailai®), and Tagitanlimab (also known as A167, brand name: Ketailai®). Notably, ADC Sacituzumab Tirumotecan has two approved indications covered under the NRDL.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments